Table 4.
Observed Outcomes for the ESLD and HF Cohorts, Patients Aged ≥65 Yearsa
| Variable | ESLD | HF |
|---|---|---|
| Index hospitalization mortalityb | 3021 (13.5%) | 3127 (3.7%) |
| Index hospitalization, discharged to hospiceb | 1446 (6.5%) | 2323 (2.7%) |
| Index hospitalization, length of stay (days)b | ||
| Mean (SD) | 9.9 (10.6) | 5.1 (5.1) |
| Median (Q1, Q3) | 7 (4, 12) | 4 (3, 6) |
| Postdischarge mortality, all-causec | ||
| One year | 8396 (46.2%) | 26,761 (34.8%) |
| Three years | 10,534 (64.9%) | 40,315 (60.8%) |
| Hospice enrollmentc | ||
| One year | 5029 (27.3%) | 13,956 (17.9%) |
| Three years | 6042 (36.1%) | 19,688 (28.9%) |
| Rehospitalization, all-causec | ||
| One year | 10,795 (59.1%) | 49,862 (63.9%) |
| Three years | 12,192 (71.0%) | 58,289 (79.6%) |
| Hepatic transplantationc | ||
| One year | 33 (0.2%) | — |
| Three years | 41 (0.3%) | — |
| Cardiac transplantationc | ||
| One year | — | 18 (<0.1%) |
| Three years | — | 23 (<0.1%) |
| Days in hospice, among those enrolledd | ||
| Mean (SD) | 43.5 (100.9) | 62.9 (126.0) |
| Median (Q1, Q3) | 9 (3, 33) | 13 (3, 59) |
| Days alive and out of the hospital, one yeare | ||
| Mean (SD) days | 209.5 (150.8) | 252.1 (135.8) |
| Median (Q1, Q3) | 273 (30, 357) | 332 (129, 362) |
| Days alive and out of the hospital, three yearse | ||
| Mean (SD) days | 496.5 (455.7) | 581.6 (432.1) |
| Median (Q1, Q3) | 353 (29, 1046) | 586 (124, 1059) |
ESLD = end-stage liver disease; HF = heart failure; Q1 = quarter 1; Q3 = quarter 3.
a
P-value for all comparisons <0.001.
b
Calculated among all patients.
c
Calculated among all patients discharged alive; hospice enrollment results include the 7.5% of ESLD patients and 2.8% of heart failure patients discharged alive who were discharged to hospice.
d
Calculated among all patients discharged alive with complete information for the follow-up period who were observed to have enrolled in hospice during the three-year follow-up period.
e
Calculated among all patients discharged alive with complete information for the follow-up period.